Board of Directors

Seth Rudnick, M.D.

Seth Rudnick, M.D.

Dr. Rudnick has extensive expertise in oncology, drug discovery and development and health care investments. For nearly a decade, he served as Board Chairman of Liquidia Technologies, helping to guide the company toward its IPO in 2018. In 2013, Dr. Rudnick retired from Canaan Partners, where he built the global venture capital firm’s capability in biopharmaceutical investing. Prior to Canaan, he was Chief Executive Officer and Chairman of CytoTherapeutics, a company developing cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Johnson & Johnson’s biotechnology company Ortho Biotech, which provides life-improving products to individuals with a focus on cancer and chronic illnesses. Dr. Rudnick received his M.D. from the University of Virginia. He also serves on the Board of Directors for G1 Therapeutics.

❮ Back to Board of Directors